Jack Eades, MD
Allergy & Immunology · Macon, GANPI 1992890727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $151,620 of the $237,287 with a category attached, or 63.9%. Pharming Healthcare, Inc. accounts for 85.2% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $91,913, 9.9 times the $9,290 reported in 2019. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 797 payments — averaging $297.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$202K
- AstraZeneca$18K
- Pfizer$7K
- CSL Behring$3K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$685
- plus $4K from 29 others
Across 12 payments — averaging $3725.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$27K
- Novartis$14K
- Chiesi USA, Inc.$3K
What the payments were for
- Consulting fees$151,62064%
- Speaking & faculty fees$41,82818%
- Travel & lodging$27,45412%
- Food & beverage$16,3747%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 259 | $202,090 |
| AstraZeneca | 75 | $18,045 |
| Pfizer | 71 | $6,657 |
| CSL Behring | 132 | $2,864 |
| GSK | 31 | $2,703 |
| Regeneron Healthcare Solutions, Inc. | 29 | $685 |
| Octapharma USA, Inc. | 12 | $656 |
| Biocryst US Sales Co., LLC | 22 | $577 |
| Genentech USA, Inc. | 15 | $388 |
| Kaleo, Inc. | 16 | $281 |
| Teva Pharmaceuticals USA, Inc. | 36 | $275 |
| Amgen(2 entities) | 12 | $237 |
| Optinose US, Inc. | 11 | $214 |
| AbbVie | 5 | $201 |
| Sanofi | 9 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $181 |
| Novartis | 8 | $158 |
| Grifols USA, LLC | 8 | $128 |
| Merck | 10 | $112 |
| Hikma Pharmaceuticals USA | 5 | $95 |
| Eyevance Pharmaceuticals LLC | 3 | $59 |
| Hospira, Inc. | 3 | $58 |
| Incyte Corporation | 1 | $57 |
| Phadia US Inc. | 3 | $57 |
| Covis Pharma GmbH | 2 | $49 |
| Boehringer Ingelheim | 2 | $39 |
| Circassia Inc. | 2 | $36 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 2 | $27 |
| ADMA Biomanufacturing LLC | 1 | $25 |
| Regeneron | 1 | $24 |
| Shire North American Group Inc | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Jubilant Hollisterstier LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$237,287 in reported general payments places this provider in the 95th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $18,605 |
| Ipratropium Bromide | 31 | $696 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $649 |
| Famotidine | 22 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $2,703 | $18,60520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Macon
- Jeffrey LangfordMacon$13K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.